These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36822966)

  • 21. Anti-cocaine vaccines: antibody protection against relapse.
    Kantak KM
    Expert Opin Pharmacother; 2003 Feb; 4(2):213-8. PubMed ID: 12562311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents.
    Ben-Yehuda A; Joseph A; Barenholz Y; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Galprin I; Glück R; Zurbriggen R; Kedar E
    Vaccine; 2003 Jul; 21(23):3169-78. PubMed ID: 12804845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cocaine Vaccine Development: Evaluation of Carrier and Adjuvant Combinations That Activate Multiple Toll-Like Receptors.
    Kimishima A; Wenthur CJ; Eubanks LM; Sato S; Janda KD
    Mol Pharm; 2016 Nov; 13(11):3884-3890. PubMed ID: 27717287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The GNE-KLH anti-cocaine vaccine protects dams and offspring from cocaine-induced effects during the prenatal and lactating periods.
    de Almeida Augusto PS; Pereira RLG; Caligiorne SM; Sabato B; Assis BRD; do Espírito Santo LP; Dos Reis KD; Castro Goulart GA; de Fátima Â; de Castro Lourenço das Neves M; Garcia FD
    Mol Psychiatry; 2021 Dec; 26(12):7784-7791. PubMed ID: 34381172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use.
    Havlicek DF; Rosenberg JB; De BP; Hicks MJ; Sondhi D; Kaminsky SM; Crystal RG
    PLoS One; 2020; 15(11):e0239780. PubMed ID: 33253224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticocaine catalytic antibodies.
    Deng SX; de Prada P; Landry DW
    J Immunol Methods; 2002 Nov; 269(1-2):299-310. PubMed ID: 12379369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting the clinical efficacy and potential adverse effects of a humanized anticocaine monoclonal antibody.
    Norman AB; Ball WJ
    Immunotherapy; 2012 Mar; 4(3):335-43. PubMed ID: 22401638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial.
    Kosten TR; Domingo CB; Shorter D; Orson F; Green C; Somoza E; Sekerka R; Levin FR; Mariani JJ; Stitzer M; Tompkins DA; Rotrosen J; Thakkar V; Smoak B; Kampman K
    Drug Alcohol Depend; 2014 Jul; 140():42-7. PubMed ID: 24793366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient Syntheses of Cocaine Vaccines and Their
    Kimishima A; Olson ME; Natori Y; Janda KD
    ACS Med Chem Lett; 2018 May; 9(5):411-416. PubMed ID: 29795751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence.
    Hall W; Carter L
    J Med Ethics; 2004 Aug; 30(4):337-40. PubMed ID: 15289512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flagellin as carrier and adjuvant in cocaine vaccine development.
    Lockner JW; Eubanks LM; Choi JL; Lively JM; Schlosburg JE; Collins KC; Globisch D; Rosenfeld-Gunn RJ; Wilson IA; Janda KD
    Mol Pharm; 2015 Feb; 12(2):653-62. PubMed ID: 25531528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Clarke DK; Xu R; Matassov D; Latham TE; Ota-Setlik A; Gerardi CS; Luckay A; Witko SE; Hermida L; Higgins T; Tremblay M; Sciotto-Brown S; Chen T; Egan MA; Rusnak JM; Ward LA; Eldridge JH
    Lancet Infect Dis; 2020 Apr; 20(4):455-466. PubMed ID: 31952923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
    J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.
    Evans SM; Foltin RW; Hicks MJ; Rosenberg JB; De BP; Janda KD; Kaminsky SM; Crystal RG
    Pharmacol Biochem Behav; 2016; 150-151():76-86. PubMed ID: 27697554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hapten optimization for cocaine vaccine with improved cocaine recognition.
    Ramakrishnan M; Kinsey BM; Singh RA; Kosten TR; Orson FM
    Chem Biol Drug Des; 2014 Sep; 84(3):354-63. PubMed ID: 24803171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
    Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
    Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01
    Ullah I; Bibi S; Ul Haq I; Safia ; Ullah K; Ge L; Shi X; Bin M; Niu H; Tian J; Zhu B
    Front Immunol; 2020; 11():1806. PubMed ID: 33133057
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
    Alberer M; Gnad-Vogt U; Hong HS; Mehr KT; Backert L; Finak G; Gottardo R; Bica MA; Garofano A; Koch SD; Fotin-Mleczek M; Hoerr I; Clemens R; von Sonnenburg F
    Lancet; 2017 Sep; 390(10101):1511-1520. PubMed ID: 28754494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.